Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

When the brain's molecular "brake" breaks, things get big. A new study reveals that mutations in the Pten gene cause individual brain progenitor cells to overproduce both neurons and astrocytes — and make them larger — helping explain the abnormal brain enlargement seen in PTEN Hamartoma Tumor Syndrome. The findings also point to the MAPK pathway as a potential new therapeutic target for related brain tumors.
Think of the Pten gene as the brain's growth regulator. When it's working properly, it keeps cell division in check during brain development. But a new study published in Science Advances by researchers at the Institute of Science and Technology Austria (ISTA) shows what happens when that brake fails — even in just a handful of individual cells.
Using a technique called lineage tracing (essentially building a "cellular family tree"), the team tracked radial glial cells — the brain's key progenitor cells — with and without Pten. The results were striking: cells lacking Pten produced about 25% more neurons than normal, along with significantly more astrocytes (the brain's support cells). Both cell types were also physically larger. This combination likely drives megalencephaly, the abnormal brain enlargement associated with PTEN mutations.
The study also uncovered a signaling twist: when both Pten and Egfr were switched off, cells bypassed the usual EGFR communication route and shifted to the MAPK pathway instead — a finding with real treatment implications.
Key Takeaways:
Why it matters: This research offers the first cell-level explanation of how Pten mutations lead to brain overgrowth, and opens a new avenue for treating drug-resistant brain tumors in patients with PTEN Hamartoma Tumor Syndrome.